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Introduction
G-CSF was initially identified as a growth factor for neutrophils [1] . Inflammatory stimuli can induce G-CSF production from bone marrow stromal cells, endothelial cells, macrophages and fibroblasts. The G-CSF receptor (G-CSFR, CD114) is expressed on early myeloid progenitors, mature granulocytes, monocytes/ macrophages [1] , endothelial cells and other non-hematopoietic tissues [2] , and also on human T and B cells [3] [4] [5] . G-CSF induces the proliferation of granulocyte progenitors and activates the effector functions of mature neutrophils [1] ; moreover, G-CSF induces the proliferation and the differentiation of HSC. Consequently, its current major clinical applications are the acceleration of neutrophil reconstitution after myelo-suppression and the mobilization of bone marrow HSC [6] . G-CSF also induces expansion [7] [8] [9] and enhancement of phagocytosis [8] of the monocyte/macrophage system. G-CSF modulates T-cell and DC functions [10, 11] . PBMC of G-CSF-treated healthy volunteers show a reduction of proinflammatory cytokines upon LPS stimulation [7, [12] [13] [14] [15] [16] [17] . The proliferation of T cells from G-CSF-treated patients [9] and healthy stem cell donors [18, 19] is profoundly reduced, due to a G1 arrest in T-cell cycle [20, 21] . This modulation might be indirectly mediated by down-regulation of co-stimulatory molecules and enhancement of IL-10 production by monocytes [18, 19, 22, 23] . Moreover, CD4
1 T cells from G-CSF-mobilized stem cell donors are able to suppress allo-proliferative responses of autologous T cells in a cell contact-independent manner, acquiring a type 1 Treg (Tr1)-like cytokine profile [24] . Importantly, direct exposure of human T cells to G-CSF in vitro does not induce Tr1 cell differentiation [19, 24, 25] . By contrast, in vivo administration of G-CSF in mouse models promotes transplantation tolerance through Tr1 cell induction [26] , and has been proved to be protective in several disease models [27] [28] [29] [30] . DC are highly specialized APC with unique capacity to activate naïve and memory T cells. In addition, DC are implicated in the maintenance of peripheral tolerance. G-CSF preferentially mobilizes plasmacytoid DC that, in turn, skew T-cell differentiation toward a Th2 phenotype [31] . Moreover, CD14
1 monocytes, in the presence of autologous serum from G-CSF-mobilized healthy donors (post-G serum), containing high levels of IL-10 and IFN-a, give rise to tolerogenic Tr1-inducing HLA-DR
low DC (post-G DC) [32] . Similarly, tolerogenic APC precursors able to induce IL-10-producing Treg arise in mice after G-CSF treatment [33] . Altogether, these findings indicate that G-CSF in vivo is an inducer of IL-10, which is implicated in the differentiation and function of tolerogenic DC [34] and Tr1 cells [35] . However, so far nobody has ever tested the direct effect of G-CSF during monocyte-derived DC (moDC) differentiation.
In this report, we show that monocytes differentiated with G-CSF and IL-4 (G-DC) acquire a DC-like morphology, with upregulation of co-stimulatory molecules, spontaneous IL-10 release, and low IL-12 production upon LPS stimulation. G-DC induce anergic but not suppressive T cells in vitro.
Results

G-CSF drives the differentiation of DC-like cells similar to post-G DC
G-DC were differentiated from peripheral blood monocytes in the presence of G-CSF and IL-4 and compared to immature DC (iDC) differentiated with GM-CSF and IL-4 for 7 days, which in some cases were exposed to LPS during the last 2 days of culture to obtain mature DC (mDC). G-DC were differentiated in the absence of GM-CSF since it masked the effects of G-CSF in terms of phenotype and cytokine production (data not shown) [36] . The yield of G-DC was 6077.5% less than iDC (n 5 38). A small portion of G-DC cultures maintained monocyte features, while most cells became large and granular; neither of the two populations attached to the plate (data not shown). The most represented portion of G-DC displayed a DC-like morphology with eccentric nucleus, large cytoplasm and tiny protrusions, and was clearly distinct from monocytes, which were smaller and with the typical bean-shaped nucleus. G-DC were similar to iDC, although larger, with more granules and dendrites (Fig. 1A) .
Moreover, G-DC did not express CD115 and M-DC8 (data not shown).
G-DC expressed CD14 but not CD1a (Fig. 1B , upper panels), as already reported for post-G DC [32] , HGF-conditioned DC [36] and DC-10 [37, 38] . Interestingly, some CD14
1 cells also coexpressed CD16 (Fig. 1B, lower panels) . G-DC were HLA-DR
CD86
1 even in the absence of maturation stimuli (Fig. 1C) . G-DC expressed significantly higher levels of HLA-DR (70% versus 22%, p 5 0.0004), CD80 (21% versus 7%, p 5 0.0257), CD83 (on average 11% versus 4%, p 5 0.0404), and CD86 (on average 83% versus 21%, po0.0001) compared to iDC (Fig. 1C) . Conversely, compared to mDC, G-DC expressed significantly higher levels of HLA-DR (on average 70% versus 44%, p 5 0.0332) and CD80 (21% versus 6%, p 5 0.0020), but lower levels of CD83 (on average 11% versus 58%, p 5 0.0040) and CD86 (on average 83% versus 97%, po0.0001; Fig. 1C ). Interestingly, G-DC did not significantly up-regulate co-stimulatory molecules and maturation markers upon LPS stimulation (Supporting Information Fig. 1 ). Thus, G-DC are phenotipically similar to post-G and HGF-conditoned DC, which are able to induce Tr1 cell differentiation [32] and expansion of FOXP3 1 Treg [36] , respectively. Therefore, we investigated the expression of tolerogenic markers involved in Treg induction on G-DC. ILT2 was expressed at high levels by G-DC, iDC and mDC (Fig. 1D) . Interestingly, G-DC expressed significantly higher levels of ILT3 (53% versus 16%, p 5 0.0009), ILT4 (26% versus 6%, po0.0001), and HLA-G (46% versus 4%, po0.0001) compared to mDC. Moreover, G-DC expressed higher levels of ILT3 (53% versus 20%, p 5 0.0206), ILT4 (26% versus 11%, p 5 0.0046) and HLA-G (46% versus 15%, p 5 0.0087) compared to iDC (Fig. 1D) . PD-L1, PD-L2, ICOS-L and CD123 were not up-regulated on G-DC compared to iDC (data not shown).
G-DC spontaneously produce IL-10 and upon activation secrete low levels of IL-12
Similar to iDC, G-DC did not produce IL-12 or TNF-a if not stimulated, and spontaneously produced IL-6 (102782 versus 152777 pg/mL). Interestingly, G-DC spontaneously secreted higher levels of IL-10 compared to iDC (on average 175785 versus 43721 pg/mL, p 5 0.0386). Compared to mDC, unstimulated G-DC secreted significantly lower levels of IL-6 (102782 versus 8757233 pg/mL, p 5 0.0008), but significantly higher levels of IL-10 (175785 versus 0 pg/mL, p 5 0.0002; Fig. 2A) . Upon stimulation, G-DC released similar amounts of IL-10 (170.2 versus 1.570.4 ng/mL), IL-6 (2.570.5 versus 2.770.5 ng/mL), and TNF-a (1.770.4 versus 1.470.3 ng/mL), but lower levels of IL-12p70 (0.470.2 ng/mL versus 2.770.5 ng/mL, p 5 0.0025), compared to activated iDC. Upon stimulation, mDC did not produce any cytokine, apart from low levels of IL-6 and IL-10, a feature not due to cell death (as ruled out by trypan blue exclusion and/or annexin V/propidium iodide analyses; data not shown), but more likely to cell exhaustion (Fig. 2B) . Therefore, in the steady state G-DC produce IL-10, and low levels of IL-12 upon activation.
G-DC display hypo-stimulatory capacity and promote T-cell anergy
Priming of naïve CD4 TNF-a. When re-stimulated with the same allo-antigen used for their priming, T(G-DC) cells proliferated 52% less than T(mDC) cells, while T(G-DC) 1IL-10 cells proliferated 62% less than T(mDC) cells (Fig. 5A, left) . No differences were found between T(G-DC) cells and T(G-DC) 1IL-10 cells in terms of IFN-g release (71% versus 67% less IFN-g than T(mDC) cells, respectively; Fig. 5A, right) . T(G-DC) 1IL-10 cells did not show any suppressive ability on autologous T cells when added to the MLC (Fig. 5B, left) . Similar data were obtained for IFN-g production (Fig. 5B, right) . Of notice, T(G-DC) cells from one out of the three donors tested were able to suppress the proliferation of autologous T cells independently of the presence of exogenous IL-10 and neutralizing antibodies (data not shown), in line with the variability observed in the previous suppressive assay. Therefore, G-DC were unable to induce T cells with suppressive capacity even in these culture conditions.
Discussion
We demonstrate that G-CSF, in combination with IL-4, promotes the generation of a population of moDC, here called G-DC, exhibiting a peculiar phenotype. G-DC express CD14 and CD16 but not CD1a, are HLA-
, and express tolerogenic markers (ILT4 and HLA-G) involved in Tr1 cell induction [37, 38] . G-DC display hypo-stimulatory capacity and induce anergic but not suppressive T cells in vitro.
We show that G-CSF not only directly induces moDC differentiation, but also modulates their phenotype and functions in vitro. Rutella et al. demonstrated that monocytes from G-CSFtreated healthy donors, exposed to autologous (post-G) serum in the absence of exogenous cytokines, differentiate into DC-like cells (post-G DC) with tolerogenic features [32] . G-DC share some characteristics with post-G DC [32] , HGF-conditioned DC-like cells [36] , DC-10 [37, 38] and DC conditioned with serum from cancer patients [40] . These populations maintain the expression of CD14 without up-regulating CD1a, express high levels of HLA-DR and co-stimulatory molecules, produce low levels of IL-12 upon activation, and are poor stimulators.
G-DC, as well as post-G DC and DC-10, induce a Tr1-like cytokine profile and anergy in naïve T cells. However, post-G DC [32] and DC-10 [37, 38] 
induce Tr1 cells, whereas G-DC do not induce suppressive T cells. On the other hand, HGF-conditioned DC expand FOXP3
1 Treg [36] . The phenotype of post-G DC can be reproduced by culturing monocytes from G-CSF-treated healthy donors in the presence of exogenous IL-10 and IFN-a [32] , while DC-10 generation requires IL-10 in combination with GM-CSF and IL-4; by contrast, G-DC are differentiated in the absence of IL-10. We can speculate that the presence of exogenous IL-10 in the culture is essential for the in vitro generation of tolerogenic DC able to drive Tr1 cell differentiation. The failure of G-DC to induce suppressive T cells does not depend on defective IL-10 production, or on the release of IL-12 and TNF-a by activated G-DC; indeed, the addition of IL-10, together with blocking antibodies against IL-12 and TNF-a, during T-cell priming with G-DC does not result in the induction of suppressive Tr1 cells. Thus, other factors might contribute to the differential tolerogenic ability of post-G DC and G-DC. ILT2, ILT3 and ILT4 are well-characterized immune inhibitory receptors predominantly expressed on myeloid and plasmacytoid DC [41] . IL-10 and IFN-a treatment induces ILT3 and ILT4 expression on moDC, which acquire the ability to induce Treg [42] ; however, another report showed that the expression of ILT3 on DC is dispensable for the induction of Treg [43] . ILT3 is up-regulated on post-G DC, but its expression does not correlate with their ability to inhibit T-cell proliferation (Rutella S., personal communication). Accordingly, G-DC are not able to induce suppressive Tr1 cells despite the expression of ILT3. We recently demonstrated that the IL-10-driven up-regulation of ILT4 and HLA-G on DC-10, and HLA-G on T cells, is necessary for Tr1 cell induction [37, 38] . Notably, ILT4 and HLA-G were expressed at low levels by G-DC. We can speculate that the low levels of expression of ILT4 and HLA-G together with low IL-10 production by G-DC contributes to their inability to induce suppressive Tr1 cells. It has been demonstrated that direct exposure of T cells to G-CSF in vitro does not induce a regulatory phenotype [19, 24, 25] . Conversely, in vivo treatment with G-CSF in mouse models of stem cell transplantation [26, 29, 44, 45] and autoimmune diseases [46] [47] [48] resulted in induction of peripheral tolerance through IL-10-producing T cells [10] . Similarly, human T cells exposed to G-CSF in vivo acquire Tr1-like phenotype and functions [24] . Therefore, indirect mechanisms triggered by G-CSF are responsible for the induction of peripheral tolerance through Treg in vivo. Notably, IFN-a and IL-10 are increased in the serum of G-CSF-treated healthy volunteers [32] and can be implicated in Tr1 cell induction both directly [49, 50] and indirectly, by contributing to the differentiation of monocytes into tolerogenic post-G DC [32] . In addition, the direct effect of G-CSF on DC could be active also in vivo, particularly at early time points after G-CSF administration, when the G-CSF serum levels reach the concentration used in our study [51] . It is also possible that G-DC, in the presence of persistent high levels of IL-10 in vivo, further differentiate into DC-10, potent Tr1 cell inducers [37] .
Injection of G-CSF in patients affected by Crohn's disease increases IL-10-secreting T cells in peripheral blood and enhances accumulation of plasmacytoid DC in the lamina propria, resulting in clinical benefit [52] . G-CSF enhances stem cell engraftment after allogeneic HSC transplantation and prevents prolonged neutropenia, but has a neutral effect on acute GVH reaction [53] while increasing chronic GVH reaction, a phenomenon recently associated with increased Th17 differentiation [54] . These apparently contrasting effects could be ascribed to the fact that G-CSF in vivo acts on different cell types, which are not yet reconstituted at the time of G-CSF treatment (lympho-myeloid cells), or which can be dysfunctional (stromal cells) in allogeneic HSC tranplantation but not in other settings.
In conclusion, we show for the first time that G-CSF per se modulates monocyte differentiation toward tolerogenic DC and directly modulates DC function. Our findings broaden the knowledge of the tolerogenic properties of G-CSF, adding a potential new mechanism of direct APC modulation, which could contribute to the induction of Treg in vivo.
Materials and methods
Cell preparation
Human peripheral blood was obtained from healthy donors in accordance with local committee approval and informed consent from all participating subjects was obtained. PBMC were separated by density gradient centrifugation over Lymphoprep (Nycomed Amersham). 
DC differentiation
CD14
1 monocytes were isolated as the adherent fraction of PBMC following 1 h incubation in RPMI 1640 (Biowhittaker) supplemented with 10% FBS (Biowhittaker), 100 U/mL penicillin/streptomycin (Bristol-Myers Squibb), and 50 mM 2-mercaptoethanol (BioRad) (DC medium) at 371C. Following extensive washing, adherent monocytes were cultured for 7 days in: 50 ng/mL rhG-CSF (Myelostim, Sanofi-Aventis) and 10 ng/mL rhIL-4 (R&D Systems) (G-DC); 100 ng/mL rhGM-CSF (R&D Systems) and 10 ng/mL rhIL-4 (iDC); 100 ng/mL rhGM-CSF and 10 ng/mL rhIL-4, with the addition of 1 mg/mL LPS (Sigma Aldrich) during the last 2 days of culture (mDC). On day 7, 10 5 differentiated DC were cytospinned 5 0 at 800 rpm. Slides were then stained with May Grünwald-Giemsa solutions (10 0 RT). DC were tested for expression of CD1a, CD14, HLA-DR, CD11c, CD80, CD83, CD86, CD123, ILT2 (BD Biosciences), ILT3 (Coulter Immunotech), ILT4 (Beckman Coulter) and HLA-G (Exbion). ICOS-L, PD-L1 and PD-L2 were from eBioscience.
T-cell purification and differentiation 
Statistical analysis
All statistical analyses for significant differences were performed with the non-parametric Mann-Whitney test. P-Values r0.05 were considered significant.
